Linagliptin Formulation Stability and Dissolution via Excipient Selection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Linagliptin, a DPP-4 inhibitor for type 2 diabetes, faces stability and content uniformity challenges due to its primary amine group reactivity with excipients like croscarmellose sodium, leading to degradation and bioavailability issues in solid dosage forms.
Innovation Solution
The formulation incorporates croscarmellose sodium as a disintegrant, along with dibasic calcium phosphate for stability and sodium stearyl fumarate as a lubricant, eliminating the need for magnesium stearate, to achieve content uniformity and improved dissolution profiles without milling, using pullulan as a binder and silicon dioxide as a glidant, and coating for moisture protection.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If croscarmellose sodium is used as a disintegrant to achieve content uniformity, then content uniformity is improved, but stability deteriorates due to reaction with primary amine group
Solution Approach 1:
The patent removes croscarmellose sodium from the formulation to eliminate the harmful reaction with the primary amine group of linagliptin, thereby resolving the stability issue while maintaining content uniformity through alternative means
Solution Approach 2:
The patent introduces an alternative disintegrant that does not contain reactive groups capable of interacting with the primary amine of linagliptin, serving as a safe intermediary that achieves disintegration without compromising stability
2Ease of manufacture
If magnesium stearate is used as a lubricant, then ease of manufacture is improved, but dissolution deteriorates
Solution Approach 1:
The patent replaces magnesium stearate with sodium stearyl fumarate, a lubricant that provides adequate manufacturing ease without the persistent negative effect of prolonged dissolution time, effectively trading one lubricant for a superior alternative
3Manufacturing precision
If active substance is milled to ensure adequate content uniformity, then content uniformity is improved, but manufacturing complexity increases
Solution Approach 1:
The patent eliminates the milling step from the manufacturing process by formulating linagliptin with excipients that provide adequate content uniformity without requiring size reduction, thereby simplifying the manufacturing process while maintaining content uniformity
Solution Approach 2:
The patent changes the formulation parameters by selecting excipients with appropriate particle size distributions and properties that enable direct compression or granulation without milling, achieving content uniformity through formulation design rather than mechanical processing
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation achieves content uniformity of less than 3.0% RSD, enhanced stability, and rapid dissolution of linagliptin, with 75-90% of the drug dissolving within 45 minutes, improving bioavailability and shelf life.
Implementation Method 1
croscarmellose sodium was used as a disintegrant
Implementation Method 2
dibasic calcium phosphate for stability
Implementation Method 3
sodium stearyl fumarate as a lubricant
Implementation Method 4
pullulan as a binder
Implementation Method 5
silicon dioxide as a glidant
Implementation Method 6
coating for moisture protection
Implementation Method 7
rapid dissolution of linagliptin, with 75-90% of the drug dissolving within 45 minutes
Data Source
AI summary
A pharmaceutical formulation for therapeutically effective amount of linagliptin or pharmaceutically acceptable salt thereof comprising croscarmellose sodium and at least one other pharmaceutically acceptable excipient.